Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
P. ovale
P. vivax
malaria
primaquine
relapse
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
09 04 2022
09 04 2022
Historique:
received:
07
05
2021
pubmed:
4
7
2021
medline:
13
4
2022
entrez:
3
7
2021
Statut:
ppublish
Résumé
The effect of primaquine in preventing Plasmodium vivax relapses from dormant stages is well established. For Plasmodium ovale, the relapse characteristics and the use of primaquine is not as well studied. We set to evaluate the relapsing properties of these 2 species, in relation to primaquine use among imported malaria cases in a nonendemic setting. We performed a nationwide retrospective study of malaria diagnosed in Sweden 1995-2019, by reviewing medical records of 3254 cases. All episodes of P. vivax (n = 972) and P. ovale (n = 251) were selected for analysis. First time relapses were reported in 80/857 (9.3%) P. vivax and 9/220 (4.1%) P. ovale episodes, respectively (P < .01). Without primaquine, the risk for relapse was higher in P. vivax, 20/60 (33.3%), compared to 3/30 (10.0%) in P. ovale (hazard ratio [HR] 3.5, 95% confidence interval [CI] 1.0-12.0). In P. vivax, patients prescribed primaquine had a reduced risk of relapse compared to episodes without relapse preventing treatment, 7.1% vs 33.3% (HR 0.2, 95% CI .1-.3). In P. ovale, the effect of primaquine on the risk of relapse did not reach statistical significance, with relapses seen in 2.8% of the episodes compared to 10.0% in patients not receiving relapse preventing treatment (HR 0.3, 95% CI .1-1.1). The risk of relapse was considerably lower in P. ovale than in P. vivax infections indicating different relapsing features between the two species. Primaquine was effective in preventing P. vivax relapse. In P. ovale, relapse episodes were few, and the supportive evidence for primaquine remains limited.
Sections du résumé
BACKGROUND
The effect of primaquine in preventing Plasmodium vivax relapses from dormant stages is well established. For Plasmodium ovale, the relapse characteristics and the use of primaquine is not as well studied. We set to evaluate the relapsing properties of these 2 species, in relation to primaquine use among imported malaria cases in a nonendemic setting.
METHODS
We performed a nationwide retrospective study of malaria diagnosed in Sweden 1995-2019, by reviewing medical records of 3254 cases. All episodes of P. vivax (n = 972) and P. ovale (n = 251) were selected for analysis.
RESULTS
First time relapses were reported in 80/857 (9.3%) P. vivax and 9/220 (4.1%) P. ovale episodes, respectively (P < .01). Without primaquine, the risk for relapse was higher in P. vivax, 20/60 (33.3%), compared to 3/30 (10.0%) in P. ovale (hazard ratio [HR] 3.5, 95% confidence interval [CI] 1.0-12.0). In P. vivax, patients prescribed primaquine had a reduced risk of relapse compared to episodes without relapse preventing treatment, 7.1% vs 33.3% (HR 0.2, 95% CI .1-.3). In P. ovale, the effect of primaquine on the risk of relapse did not reach statistical significance, with relapses seen in 2.8% of the episodes compared to 10.0% in patients not receiving relapse preventing treatment (HR 0.3, 95% CI .1-1.1).
CONCLUSIONS
The risk of relapse was considerably lower in P. ovale than in P. vivax infections indicating different relapsing features between the two species. Primaquine was effective in preventing P. vivax relapse. In P. ovale, relapse episodes were few, and the supportive evidence for primaquine remains limited.
Identifiants
pubmed: 34216464
pii: 6314296
doi: 10.1093/cid/ciab610
pmc: PMC8994585
doi:
Substances chimiques
Antimalarials
0
Primaquine
MVR3634GX1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199-1207Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet. 2019 Jul 27;394(10195):332-343
pubmed: 31229233
Malar J. 2011 Oct 11;10:297
pubmed: 21989376
Clin Infect Dis. 2019 Nov 27;69(12):2119-2126
pubmed: 31066448
Am J Trop Med Hyg. 2020 Sep;103(3):1094-1099
pubmed: 32524950
Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389
pubmed: 24163057
Malar J. 2017 Mar 11;16(1):112
pubmed: 28284211
Euro Surveill. 2019 Jan;24(5):
pubmed: 30722809
Adv Parasitol. 2012;80:113-50
pubmed: 23199487
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):15-34
pubmed: 27402513
Clin Infect Dis. 2017 Sep 15;65(6):949-958
pubmed: 28510633
PLoS Med. 2015 Oct 27;12(10):e1001891
pubmed: 26505753
Trop Dis Travel Med Vaccines. 2017 Mar 28;3:7
pubmed: 28883977
J Infect Dis. 2019 Sep 13;220(8):1335-1345
pubmed: 31175365
Malar J. 2019 Mar 28;18(1):104
pubmed: 30922316
Lancet. 2019 Sep 14;394(10202):929-938
pubmed: 31327563
N Engl J Med. 2019 Jan 17;380(3):229-241
pubmed: 30650326
Malar J. 2018 Feb 9;17(1):78
pubmed: 29426330
N Engl J Med. 2019 Jan 17;380(3):215-228
pubmed: 30650322
Clin Infect Dis. 2004 Nov 1;39(9):1336-45
pubmed: 15494911
Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900
pubmed: 27530139
BMC Med. 2018 Nov 27;16(1):218
pubmed: 30477484
PLoS Med. 2021 Apr 23;18(4):e1003561
pubmed: 33891587
Malar J. 2014 Apr 15;13:144
pubmed: 24731298
Lancet Infect Dis. 2018 Sep;18(9):1025-1034
pubmed: 30033231
Tunis Med. 2015 Jun;93(6):347-9
pubmed: 26644094
PLoS Negl Trop Dis. 2018 Apr 19;12(4):e0006230
pubmed: 29672516
PLoS Negl Trop Dis. 2019 May 28;13(5):e0007414
pubmed: 31136585
Cochrane Database Syst Rev. 2019 Jul 05;7:CD012656
pubmed: 31274189
Parasitol Res. 2010 Nov;107(6):1285-90
pubmed: 20922429
mBio. 2018 May 8;9(3):
pubmed: 29739900
J Clin Microbiol. 2009 Apr;47(4):975-80
pubmed: 19244467